DNA甲基化修饰在乳腺癌中的研究进展OA

Breast cancer is the most common malignant tumor in women worldwide.Genomic mutations and epigenetic dysregulation can drive tumor drug resistance,recurrence,and metastasis.As a common epigenetic modification,DNA methylation modification is involved in the occurrence,development and chemotherapy resistance of breast cancer by dynamically regulating gene expression.This review summarizes the regulatory functions of DNA methylation and demethylation modifications in breast cancer,revealing how their dysregulation drives disease progression by modulating malignant phenotypes such as proliferation,metastasis,metabolic reprogramming,and immune evasion.At the same time,abnormal DNA methylation can lead to silencing of tumor suppressor genes or activation of oncogenes,and mediates the resistance of breast cancer to chemotherapeutic drugs.DNA methyltransferase(DNMT)inhibitors can activate silent genes through demethylation,enhance chemotherapy sensitivity,and show synergistic anti-tumor potential in combination with other drugs.Furthermore,the potential applications of personalized therapy are discussed.Future efforts should focus on identifying breast cancer subtype-specific methylation biomarkers and optimizing combination treatment strategies to overcome drug resistance and improve therapeutic efficacy,thereby providing novel epigenetic strategies for precision therapy in breast cancer.